Document is current
Any future updates will be listed below
-
Authors
SANOMACHI, Tomomi
YOSHIDA, Tatsuya
HIGASHIYAMA, Ryoko INABA
SATOZONO, Yaya
MATSUNAGA, Shiho
KANEMITSU, Yukihide
OHE, Yuichiro
- License Information
-
More Information
Article History
Received: 9 April 2024
Accepted: 4 June 2024
First Online: 13 June 2024
Declarations
:
: Tatsuya YOSHIDA reports personal fees from Novartis, personal fees from AbbVie, personal fees from Amgen, personal fees from Daiichi-Sankyo, personal fees from AstraZeneca, personal fees from MSD, personal fees from Chugai, personal fees from Astellas, personal fees from Medpace, personal fees from Boehringer Ingelheim, personal fees from BMS, personal fees from Takeda, personal fees from Pfizer, personal fees from Lilly, personal fees from ONO, personal fees from Merck.Yuichiro OHE reports personal fees from AstraZeneca, personal fees from Chugai, personal fees from Lilly, personal fees from ONO, personal fees from BMS, personal fees from Boehringer Ingelheim, personal fees from Bayer, personal fees from Pfizer, personal fees from MSD, personal fees from Taiho, personal fees from Nippon Kayaku, personal fees from Kyowa Hakko Kirin, personal fees from Eisai, personal fees from Daiichi-Sankyo.
: The study participant provided informed consent, and the study design was approved by the appropriate ethics review board.
